Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. - Wikidata - awgldk - TriplyDB

Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib.

Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib.

http://www.wikidata.org/entity/Q41899379

about

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.CCR 20th Anniversary Commentary: A Genetic Mechanism of Imatinib Resistance in Gastrointestinal Stromal Tumor-Where Are We a Decade Later?Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor.Primordial germ cells and gastrointestinal stromal tumors respond distinctly to a cKit overactivating allele Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling.Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors: present and future.Therapeutic targeting of tumor-stroma interactions.The benefit of using CT-perfusion imaging for reliable response monitoring in patients with gastrointestinal stromal tumor (GIST) undergoing treatment with novel targeted agents.Treatments for gastrointestinal stromal tumors that are resistant to standard therapies.Molecular changes associated with the development of resistance to imatinib in an imatinib-sensitive canine neoplastic mast cell line carrying a KIT c.1523A>T mutation.New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis.ETV1-Positive Cells Give Rise to BRAFV600E -Mutant Gastrointestinal Stromal Tumors.A Novel Role of a Chemotherapeutic Agent in a Rat Model of Endotoxemia: Modulation of the STAT-3 Signaling Pathway.New targets and therapies for gastrointestinal stromal tumors.Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor.

P2860

Q26740953-BF9B4434-6531-4810-9D19-9B44E07A715A Q28484181-CEC9A92C-416C-4733-9BF8-E2FDB967AF93 Q33560776-77DF5CFC-08CB-4D52-A2B6-E89ADFE5B103 Q34289180-EDC8E529-A2FD-453D-91B9-682E24CF96E3 Q35919932-42E70B2D-1667-4858-AE33-6EFC7316D7D9 Q36187383-4F0F2987-D5A5-425E-AFB9-2560D0A2F28A Q36477671-ECB3CDF9-7B53-49C8-8575-500ADED743FD Q36996552-4B3C40B4-3221-4A80-9AD2-3E5F36F615B3 Q37334711-C1A673EA-19DD-4C63-8D69-AC1EA396227F Q37850810-29DAA1B5-53FC-4937-8DB5-280AD7ED88A4 Q37851151-DF314601-5E2E-4C89-B834-FEF6AB401FB7 Q38114042-FDD0C0C2-F010-42C1-BC75-6D33C5CF0A3E Q38268165-C22D4743-6081-43E9-B65A-AB9842FD5C2C Q38909315-F313BB22-8EC7-4574-9F3D-D49B99EE65F6 Q39146365-DC0851DC-07FD-445E-82A1-01F8B9FA39AF Q46050114-E74696CE-87D6-45E3-BDFE-BA1FA43709DC Q46573219-60F48D8D-23E6-4AFC-96DE-F18A7DD86888 Q47432725-C991748A-5909-4553-A163-27D126647AFB Q48327749-6C5EB8FB-56F7-4BEA-976A-F7A1585C0C57

P2860

Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib.

http://www.wikidata.org/entity/Q41899379

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Imatinib upregulates compensat ...... when combined with dasatinib.

@en

type

label

Imatinib upregulates compensat ...... when combined with dasatinib.

@en

prefLabel

Imatinib upregulates compensat ...... when combined with dasatinib.

@en

P1433

Q41899379-B34730EE-BD4A-4AAF-8CC1-2326F5BE9055

P1476

Q41899379-CA88A800-B5E7-4A42-897A-AF7513C6BF3D

P2093

Q41899379-37AC81F6-C4C9-4E15-A671-600C3782233F

Q41899379-4363B67E-5828-43D9-931E-A9E33CBB56CB

Q41899379-5474A218-4740-46B1-A730-2CFB783A1D77

Q41899379-5E327B88-D60B-4E3E-9D6B-24A28E0FEE9F

Q41899379-63792CA3-31A3-4D53-8999-74545004EC8B

Q41899379-7102D940-1B3C-4914-9FB4-2D482FBA87AA

Q41899379-A3108185-9C53-4F2B-BDFF-197D5AB0CBBE

Q41899379-B80C9BBC-BEC7-42E7-9CC6-7E8A11B1C7B5

Q41899379-F3AC1AE3-A149-4B6E-9444-F125DC43CBC1

P2860

Q41899379-0DF762D9-8D76-499B-BDA0-5637C4E8ABEE

Q41899379-0E30A31D-79EE-4714-9F3C-644CC57C3904

Q41899379-1F1510ED-4668-43DD-BD2A-94E241D86355

Q41899379-30981A6B-95F1-484C-A9AB-B21B75776BA5

Q41899379-359EC871-40EA-4C30-8016-D75D2D877C27

Q41899379-367675FF-2594-4DAE-874B-7AFD3B65357D

Q41899379-37E3DD68-F372-4318-B15F-896A54CD14D7

Q41899379-3A4EBEC3-FACC-4380-84CF-AE280A01C0CE

Q41899379-41DCF571-2155-4076-BBD8-97AFED7D0A16

Q41899379-435BD304-E5FF-4A22-AF18-0354876D652B

P304

Q41899379-1AA41C10-442E-487B-883E-0C9A12E96359

P31

Q41899379-9B80035D-6B4F-4BAD-9490-4CCED378255F

P356

Q41899379-6C35BAD1-D328-4580-9425-EB9F7777770F

P433

Q41899379-516E3E5D-E1D1-47BD-97D3-5A15CA25961E

P478

Q41899379-E9CC45C1-6558-421D-BB23-F5DE2A23E848

P577

Q41899379-B2F14566-891B-4C0D-A814-767A5701C096

P698

Q41899379-B4D59E89-6A88-4857-BE29-7BB33A04CB81

P932

Q41899379-53C6A515-9DB8-4D72-9249-DE599E756122

P356

1541-7786.MCR-10-0065

P1433

Molecular Cancer Research

P1476

Imatinib upregulates compensat ...... when combined with dasatinib.

@en

P2093

Bayard Clarkson

http://www.w3.org/2001/XMLSchema#string

Cristina R Antonescu

http://www.w3.org/2001/XMLSchema#string

Darren Veach

http://www.w3.org/2001/XMLSchema#string

Elisa de Stanchina

http://www.w3.org/2001/XMLSchema#string

Ferdinand Rossi

http://www.w3.org/2001/XMLSchema#string

Filippo G Giancotti

http://www.w3.org/2001/XMLSchema#string

Katia Manova

http://www.w3.org/2001/XMLSchema#string

Peter Besmer

http://www.w3.org/2001/XMLSchema#string

Yasemin Yozgat

http://www.w3.org/2001/XMLSchema#string

P2860

Integrin-regulated FAK-Src signaling in normal and cancer cells

SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain.

A single immunoglobulin-like domain of the human neural cell adhesion molecule L1 supports adhesion by multiple vascular and platelet integrins

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation

Thrombospondin-1 acts via IAP/CD47 to synergize with collagen in alpha2beta1-mediated platelet activation

Lyn associates with the juxtamembrane region of c-Kit and is activated by stem cell factor in hematopoietic cell lines and normal progenitor cells

A quantitative analysis of kinase inhibitor selectivity

Signalling via integrins: implications for cell survival and anticancer strategies

Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells

P304

1271-1283

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1541-7786.MCR-10-0065

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20736294

http://www.w3.org/2001/XMLSchema#string

P932

2952175

http://www.w3.org/2001/XMLSchema#string